Longeveron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Longeveron and other ETFs, options, and stocks.

About LGVN

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. 

CEO
Stephen H. Willard
CEOStephen H. Willard
Employees
38
Employees38
Headquarters
Miami, Florida
HeadquartersMiami, Florida
Founded
2014
Founded2014
Employees
38
Employees38

LGVN Key Statistics

Market cap
7.89M
Market cap7.89M
Price-Earnings ratio
-0.25
Price-Earnings ratio-0.25
Dividend yield
Dividend yield
Average volume
264.19K
Average volume264.19K
High today
$2.80
High today$2.80
Low today
$2.30
Low today$2.30
Open price
$2.73
Open price$2.73
Volume
527.16K
Volume527.16K
52 Week high
$12.30
52 Week high$12.30
52 Week low
$2.30
52 Week low$2.30

Stock Snapshot

As of today, Longeveron(LGVN) shares are valued at $2.46. The company's market cap stands at 7.89M, with a P/E ratio of -0.25.

During the trading session on 2026-09-20, Longeveron(LGVN) shares reached a daily high of $2.80 and a low of $2.30. At a current price of $2.46, the stock is +7.0% higher than the low and still -12.1% under the high.

Trading volume for Longeveron(LGVN) stock has reached 527.16K, versus its average volume of 264.19K.

Over the past 52 weeks, Longeveron(LGVN) stock has traded between a high of $12.30 and a low of $2.30.

Over the past 52 weeks, Longeveron(LGVN) stock has traded between a high of $12.30 and a low of $2.30.

LGVN News

TipRanks 3d
Longeveron Stock Plummets 56% on a Failed Clinical Trial

Longeveron (LGVN) stock plummeted on Thursday after the biotechnology company provided investors with a clinical trial update and a warning. The company reporte...

Investing.com 3d
Longeveron stock plunges 50% after trial misses primary endpoint - Investing.com

...

Longeveron stock plunges 50% after trial misses primary endpoint - Investing.com
TipRanks 4d
Longeveron down 55% at $2.98 after resumption of trade

Shares of Longeveron (LGVN) are down 55% after the resumption of trade after the company announced that laromestrocel did not meet primary endpoint in Phase 2b...

More LGVN News

TipRanks 4d
Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial

Longeveron (LGVN) announced topline results from ELPIS II, its Phase 2b clinical trial evaluating its investigational stem cell therapy laromestrocel as an adju...

TipRanks 6d
Longeveron Regains Nasdaq Compliance With Minimum Bid Price

The latest update is out from Longeveron ( (LGVN) ). Longeveron Inc. disclosed that on September 22, 2025 it received a Nasdaq notice for failing to meet the $...

People also own

Based on the portfolios of people who own LGVN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.